Table 3.

Frequency of adverse effects and toxicities in patients undergoing PB-IORT.

		Total n=204
Category	Adverse effect	G1	G2	G3	G4	G5
Overall maximum toxicity		66 (32.4%)	27 (13.2%)	5 (2.5%)
General	Fatigue	9 (4.4%)	3 (1.5%)
	Fever	1 (0.5%)	1 (0.5%)
	Localized edema	5 (2.5%)
	Pain	2 (1.0%)	1 (0.5%)
Infection	Urinary tract infection		1 (0.5%)
	Breast infection		8 (3.9%)	2 (1.0%)
	Wound infection		2 (1.0%)	1 (0.5%)
Procedural	Radiation dermatitis	13 (6.4%)	3 (1.5%)
	Radiation reaction	2 (1.0%)
	Seroma	29 (14.2)	5 (2.5%)
	Wound dehiscence		1 (0.5%)
	Other	2 (1.0%)
Hematologic	Lymphocytopenia			1 (0.5%)
Metabolic	Hyperglycemia	1 (0.5%)
Musculoskeletal	Fibrosis (deep)	1 (0.5%)
	Fibrosis (superficial)	8 (3.9%)	1 (0.5%)
	Generalized muscle weakness			1 (0.5%)
	Extremity pain		1 (0.5%)
Reproductive/breast	Breast pain	18 (8.8%)	2 (1.0%)
	Other	6 (2.9%)	1 (0.5%)
Respiratory	Cough	1 (0.5%)
Skin	Erythema multiforme	7 (3.4%)	1 (0.5%)
	Pruritus	4 (2.0%)
	Rash maculopapular	3 (1.5%)
	Skin hyperpigmentation	8 (3.9%)
	Skin induration	1 (0.5%)	1 (0.5%)
	Other	14 (6.9%)	5 (2.5%)
Vascular	Lymphedema	2 (1.0%)
	Superficial thrombophlebitis	1 (05%)	2 (1.0%)
	Thromboembolic event			1 (0.5%)
	Other	1 (0.5%)
Unspecified				1 (0.5%)

Categorical variables listed as n (%).

^*Overall maximum toxicity denotes the number of patients that experienced a maximum toxicity of that grade.